What is Xeno Diagnostics?
Xeno Diagnostics operates at the intersection of advanced immunology and drug discovery, providing critical infrastructure for pharmaceutical research. The company specializes in custom cell-based immunoassays, with a core focus on high-stakes fields such as immuno-oncology, regenerative medicine, and transplant immunology. Their technical portfolio includes sophisticated Mixed Lymphocyte Reaction (MLR) experiments, cell isolation, and banking services, all designed to support clients through the rigorous regulatory testing required for clinical trial progression. By utilizing advanced analytical platforms like Flow Cytometry and ELISA, Xeno Diagnostics serves as a vital partner for organizations navigating the complexities of immune function evaluation and therapeutic validation.
How much funding has Xeno Diagnostics raised?
Xeno Diagnostics has raised a total of $75K across 1 funding round:
Debt
$75K
Debt (2021): $75K with participation from PPP
Key Investors in Xeno Diagnostics
PPP
Public-Private Partnership
What's next for Xeno Diagnostics?
With the successful acquisition of $75K, Xeno Diagnostics is poised to enter a phase of significant operational expansion. The company is expected to utilize this capital to enhance its laboratory infrastructure and broaden its service offerings, particularly in the high-growth sectors of regenerative medicine and oncology. As the firm transitions through its current growth stage, the focus will likely shift toward increasing throughput for clinical trial support and deepening its integration into the global pharmaceutical supply chain. This strategic deployment of resources will be essential for maintaining its competitive edge in providing high-fidelity, regulatory-compliant data for complex biological studies.
See full Xeno Diagnostics company page
